Pharmacodynamic assessments
BLOOD, SECONDARY
Pharmacodynamic activity was assessed as a secondary endpoint by measurement of metabolic and immunological variables. Blood samples, collected from all repeat-dose participants in the monotherapy and combination therapy cohorts at screening, on day 56, and at months 3, 6, 9 and 12, were analysed for HbA